In 2022, 10.2 males and 6.5 females per 100,000 population in England were registered as newly diagnosed with brain cancer. Compared to the previous year, a slight increase in the newly diagnosed thyroid cancer rates was seen for male individuals, while the female diagnose rate remained stable. This statistic shows the rate of newly diagnosed cases of brain cancer per 100,000 population in England from 1995 to 2022, by gender.

This statistic shows the amount of registrations of newly diagnosed cases of brain cancer in England in 2022, by age group. In this year, *** new cases were reported among men aged 70 to 74 years of age, and *** cases among women in this age group.

This statistic shows the registrations of newly diagnosed cases of brain cancer in England from 1995 to 2022, by gender. In 2022, 2,806 men and 2,004 women were diagnosed with brain cancer in England.

The Get Data Out programme from the National Disease Registration Service publishes detailed statistics about small groups of cancer patients in a way that ensures patient anonymity is maintained. The Get Data Out programme currently covers 15 cancer sites. This data release is a corrected re-release of detailed statistics for 2013-2019 treatment data. The correction means that surgery counts are no longer slightly underreported. There are some small changes in group sizes of usually no more than 2%, although this is larger for non-melanoma skin cancers. The 15 cancer sites now covered by Get Data Out are: ‘Bladder, Urethra, Renal Pelvis and Ureter’, ‘Bone cancer’, ‘Brain, meningeal and other primary CNS tumours’, ‘Eye cancer’, ‘Head and neck’, ‘Kaposi sarcoma’, ‘Kidney’, ‘Oesophageal and Stomach’, ‘Ovary, fallopian tube and primary peritoneal carcinomas’, ‘Pancreas’, ‘Prostate’, ‘Sarcoma’, ‘Skin tumours’, ‘Soft tissue and peripheral nerve cancer’, ‘Testicular tumours including post-pubertal teratomas’. Anonymisation standards are designed into the data by aggregation at the outset. Patients diagnosed with a certain type of tumour are divided into many smaller groups, each of which contains approximately 100 patients with the same characteristics. These groups are aimed to be clinically meaningful and differ across cancer sites. For each group of patients, Get Data Out routinely publish statistics about incidence, routes to diagnosis, treatments and survival. All releases and documentation are available on the Get Data Out main technical page. Before using the data, we recommend that you read the guide for first time users. The data is available in an open format for anyone to access and use. We hope that by releasing anonymous detailed data like this we can help researchers, the public and patients themselves discover more about cancer. If you have feedback or any other queries about Get Data Out, please email us at NDRSenquires@nhs.net and mention 'Get Data Out' in your email.

The Get Data Out programme from the National Disease Registration Service publishes detailed statistics about small groups of cancer patients in a way that ensures patient anonymity is maintained. The 19 cancer sites currently covered by Get Data Out are: ‘Bladder, urethra, renal pelvis and ureter’, ‘Bone’, ‘Brain’, ‘Eye’, ‘Blood cancer (haematological neoplasms)’, ‘Blood cancer (haematological neoplasm) transformations’, ‘Head and neck’, ‘Kaposi sarcoma’, ‘Kidney’, ‘Liver and biliary tract’, ‘Lung, mesothelioma, and other thoracic', Oesophagus and stomach’, ‘Ovary’, ‘Pancreas’, ‘Prostate’, ‘Sarcoma’, ‘Skin tumours’, ‘Soft tissue’, ‘Testes’. Anonymisation standards are designed into the data by aggregation at the outset. Patients diagnosed with a certain type of tumour are divided into many smaller groups, each of which contains approximately 100 patients with the same characteristics. These groups are aimed to be clinically meaningful and differ across cancer sites. For each group of patients, Get Data Out routinely publish statistics about incidence, routes to diagnosis, treatments and survival. This release covers the addition of the diagnosis year 2022 for treatment, plus a refresh of the 2013-2021 treatment data. This is also a first release of a new 'Visualisations' tab on our dashboard which will allow the user to explore the GDO data in graphical and tabular form. Users will now be able to select a single GDO group using drop down menus and display figures of incidence, demographic, treatment, routes to diagnosis, and survival statistics by diagnosis year. Finally, this is a small update to the 2013-2022 incidence data to include more age standardised rates (ASRs) for gender specific groups (genital skin groups for example which previously did not have an ASR published). All releases and documentation are available on the Get Data Out dashboard. Before using the data, we recommend that you read the 'Introduction', 'FAQs' and 'Known limitations' tabs. The data is available in an open format for anyone to access and use. We hope that by releasing anonymous detailed data like this we can help researchers, the public and patients themselves discover more about cancer. If you have feedback or any other queries about Get Data Out, please email us at NDRSenquires@nhs.net and mention 'Get Data Out' in your email.

Snapshot img

Glioblastoma Multiforme Treatment Market Size 2024-2028

The glioblastoma multiforme treatment market size is forecast to increase by USD 1.36 billion at a CAGR of 8.2% between 2023 and 2028.

The glioblastoma multiforme (GBM) treatment market is experiencing significant growth due to the rising incidence of this aggressive brain cancer and increasing research and development activities In the healthcare sector. According to the American Brain Tumor Association's Cancer Observatory, GBM accounts for approximately 15% of all primary brain tumors and is the most common malignant brain tumor in adults. Current treatment options include surgery, targeted therapy, and chemotherapy. Surgery remains the primary treatment modality for GBM, with various options such as awake craniotomy and awake craniotomy with intraoperative monitoring. This includes various strategies such as checkpoint inhibitors, monoclonal antibodies, and gene therapy. However, these procedures come with adverse effects such as cognitive impairment and motor deficits. Targeted therapies, such as temozolomide, are used in conjunction with surgery and chemotherapy to improve patient outcomes. The pharmaceutical supply chain plays a crucial role in ensuring the timely availability of these treatments to patients. Despite advancements in treatment options, the high mortality rate associated with GBM necessitates continued research and development efforts to improve patient outcomes and quality of life.

What will be the Size of the Glioblastoma Multiforme Treatment Market During the Forecast Period?

Request Free Sample

Glioblastoma multiforme (GBM), a malignant tumor of the central nervous system (CNS), is a significant health concern worldwide. According to the Global Cancer Observatory, CNS cancers accounted for approximately 2.3% of all cancer diagnoses and 2.5% of cancer deaths in 2020. This article provides an overview of the current treatment landscape for GBM, focusing on surgical, radiation, chemotherapy, targeted therapy, immunotherapy, and emerging novel therapies. Surgery is the primary treatment modality for GBM, with the primary goal being to remove as much of the tumor as possible while minimizing damage to healthy brain tissue. Ambulatory surgical centers and hospitals offer various surgical procedures, including craniotomy and awake craniotomy. Following surgery, patients typically undergo radiation therapy to target any remaining cancer cells. External beam radiation therapy (EBRT) is the most common approach, delivering high-energy radiation to the tumor site. Chemotherapy is often used in combination with radiation therapy to enhance the therapeutic effect.
Moreover, temozolomide, a chemotherapeutic agent, is the most widely used drug for GBM treatment. Corticosteroids, such as dexamethasone, are also frequently administered to reduce swelling and improve symptoms. Targeted therapies, such as bevacizumab, are designed to specifically target the molecular mechanisms of GBM. These therapies inhibit the growth and spread of cancer cells by blocking the action of specific proteins. Moreover, combination Therapies: Combination therapies, which involve the use of multiple treatment modalities, are increasingly being explored to improve treatment outcomes for GBM. For example, the combination of temozolomide and radiation therapy has been shown to improve survival rates compared to monotherapy. Immunotherapy: Immunotherapy, which harnesses the power of the immune system to fight cancer, is an emerging treatment approach for GBM. Personalized Medicine: The heterogeneity of GBM necessitates personalized treatment approaches.
Thus, drug classes and treatment procedures are being tailored to individual patients based on their unique tumor characteristics, such as genetic mutations and protein expression profiles. The treatment market for GBM is continually evolving, with a focus on developing novel therapies and combination strategies to improve patient outcomes. The pharmaceutical supply chain plays a crucial role in ensuring the availability and accessibility of these treatments. As the understanding of GBM biology deepens, so too will the range and effectiveness of treatment options.

How is this Glioblastoma Multiforme Treatment Industry segmented and which is the largest segment?

The glioblastoma multiforme treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals
  Clinics
  Ambulatory surgical centers


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period.

The

Purpose:Cystatin C (CysC), beyond its biomarker role of renal function, has been implicated in various physical and pathological activities. However, the impact of serum CysC on cancer mortality in a general population remains unknown. We aimed to examine the associations of serum CysC concentrations with total mortality and mortality of 12 site-specific cancers.Methods:We included 241,008 participants of the UK Biobank cohort with CysC measurements who had normal creatinine-based estimated glomerular filtration rates and were free of cancer and renal diseases at baseline (2006–2010). Death information was obtained from the National Health Service death records through 28 February 2021. Multivariable Cox proportional hazards models were used to compute hazard ratios (HR) per one standard deviation increase in log-transformed CysC concentrations and 95% confidence intervals (95% CI) for mortality.Results:Over a median follow-up of 12.1 (interquartile range, 11.3–12.8) years, 5,744 cancer deaths occurred. We observed a positive association between serum CysC concentrations and total cancer mortality (HR = 1.16, 95% CI: 1.12–1.20). Specifically, participants with higher serum CysC concentrations had increased mortality due to lung cancer (HR = 1.12, 95% CI: 1.05–1.20), blood cancer (HR = 1.29, 95% CI: 1.16–1.44), brain cancer (HR = 1.19, 95% CI: 1.04–1.36), esophageal cancer (HR = 1.20, 95% CI: 1.05–1.37), breast cancer (HR = 1.18, 95% CI: 1.03–1.36), and liver cancer (HR = 1.49, 95% CI: 1.31–1.69).Conclusion:Our findings indicate that higher CysC concentrations are associated with increased mortality due to lung, blood, brain, esophageal, breast, and liver cancers. Future studies are necessary to clarify underlying mechanisms.

Snapshot img

Brain Tumor Diagnostics Market Size 2024-2028

The brain tumor diagnostics market size is forecast to increase by USD 152.9 million, at a CAGR of 3.4% between 2023 and 2028.

The market is experiencing significant growth, driven by the increasing prevalence of brain cancer and advancements in research and development. The rise in brain cancer cases is fueled by an aging population, increased awareness, and improved diagnostic techniques. Simultaneously, technological innovations, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, are revolutionizing the diagnostic landscape, enabling earlier and more accurate detection of brain tumors. However, the market faces challenges, including an unfavorable reimbursement scenario, which can hinder the adoption of advanced diagnostic technologies. Healthcare systems and insurance providers often limit coverage for expensive diagnostic procedures, making it difficult for patients to access these services. To navigate this challenge, companies must collaborate with payers and healthcare providers to develop cost-effective solutions and demonstrate the clinical and economic value of their offerings. By addressing these challenges and capitalizing on the market's growth drivers, companies can seize opportunities and shape the future of brain tumor diagnostics.

What will be the Size of the Brain Tumor Diagnostics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free SampleThe market continues to evolve, driven by advancements in technology and research. Brain tumor segmentation, a crucial aspect of diagnostics, is undergoing constant refinement through neurological examinations and various imaging techniques. Optical coherence tomography (OCT) and neuropsychological testing offer non-invasive alternatives to traditional diagnostic methods. The diagnostic imaging workflow is being streamlined with the integration of pet scan tracers and radiomics feature extraction. Near-infrared spectroscopy and contrast-enhanced CT provide additional insights into tumor characteristics. Perfusion MRI techniques, magnetic resonance spectroscopy, and liquid biopsy markers are also gaining traction. Machine learning algorithms, deep learning models, and computer-aided detection are revolutionizing the field, enabling more accurate and efficient diagnoses. Advanced neuroimaging techniques, such as diffusion tensor imaging, functional MRI studies, and tumor vascularity assessment, offer enhanced visualization of brain structures and tumors. Molecular imaging agents, tissue microarray analysis, and immunohistochemical staining provide valuable information on the tumor microenvironment. Pituitary adenoma imaging and meningioma detection are specific applications of these techniques. Image registration algorithms, gene expression profiling, and glioblastoma characterization are other areas of ongoing research. The use of artificial intelligence diagnostics, exosome-based diagnostics, and advanced imaging technologies continues to unfold, offering new possibilities for improved brain tumor diagnostics. This dynamic landscape underscores the importance of staying informed and adaptable in this rapidly evolving market.

How is this Brain Tumor Diagnostics Industry segmented?

The brain tumor diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. TypeImaging testBiopsyMolecular testingOthersGeographyNorth AmericaUSCanadaMexicoEuropeFranceGermanyUKMiddle East and AfricaSouth AfricaAPACChinaIndiaJapanRest of World (ROW)

By Type Insights

The imaging test segment is estimated to witness significant growth during the forecast period.The market is experiencing significant advancements, driven by the increasing prevalence of brain tumors and cancer. Neurological examinations remain the initial diagnostic method, but medical imaging techniques, such as optical coherence tomography, neuropsychological testing, and diagnostic imaging workflows, are increasingly utilized for more accurate and timely diagnoses. Advanced imaging modalities, including pet scan tracers, radiomics feature extraction, near-infrared spectroscopy, contrast-enhanced CT, perfusion MRI techniques, magnetic resonance spectroscopy, and molecular imaging agents, are revolutionizing brain tumor diagnostics. Liquid biopsy markers and gene expression profiling are also gaining popularity for their non-invasive nature and potential for early detection. Machine learning algorithms, deep learning models, and artificial intelligence diagnostics are being integrated into imaging systems to enhance accuracy and efficiency. Image-guided biopsies, cell-free

Metastatic brain tumor has been associated with high mortality and poor prognosis. However, information on indicators predicting surgical prognosis in patients with brain metastases is limited. This study aimed to investigate the association between preoperative red blood cell distribution width (RDW) and mortality in patients who underwent surgery for metastatic brain tumors. This study analyzed 282 patients who underwent metastatic brain tumor surgery between August 1999 and March 2020. Patients were divided into two groups based on preoperative RDW cut-off values (

Snapshot img

Radiation Oncology Market Size 2024-2028

The radiation oncology market size is forecast to increase by USD 1.94 billion at a CAGR of4.34% between 2023 and 2028.

In the market, the primary drivers include the increasing incidence of cancer and the rise in healthcare expenditure. As cancer continues to be a significant health concern, the demand for advanced radiation therapy techniques, such as seeds and stereotactic therapy, is increasing. These treatments offer therapeutic benefits by targeting abnormal cells with precision, reducing the impact on healthy cells. Technological developments, including advanced treatment planning software, tumor tracking systems, artificial intelligence, and machine learning, enable more effective and personalized treatment plans. However, challenges persist, including the lack of access to radiotherapy in certain regions and the high cost of these advanced treatments. Despite these challenges, the market is expected to grow, driven by the potential for improved patient outcomes and the ongoing technological advancements In the field.

What will be the Size of the Radiation Oncology Market During the Forecast Period?

Request Free Sample

The market is a significant segment of the healthcare industry, focusing on the delivery of radiation therapy to treat various types of cancer. This form of oncology treatment, also known as radiotherapy, utilizes high-energy radiation to destroy tumor cells. Radiation oncology plays a crucial role in cancer treatment, with breast cancer, metastatic melanoma, and neuroendocrine cancers being some of the common indications. The increasing prevalence of cancer and the growing demand for advanced therapeutic benefits have driven the market's growth. Regulatory scrutiny remains a critical factor In the market.



Stringent regulations ensure the safety and efficacy of radiotherapy devices and treatment planning software. These regulations also apply to advanced technologies like proton therapy, which offers improved therapeutic benefits for certain types of cancer. Imaging data plays a pivotal role in radiation oncology. Accurate and timely access to imaging data is essential for effective treatment planning and delivery. Cancer treatment centers and oncology research institutes are investing in advanced imaging technologies to enhance their capabilities. Technological developments in radiation oncology are continually evolving. Companies are focusing on improving the precision, efficiency, and patient experience of radiotherapy. Radiotherapy devices, such as those manufactured by Elekta and Gamma Knife, are being enhanced with innovative features.

How is this Radiation Oncology Industry segmented and which is the largest segment?

The radiation oncology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  EBRT
  Brachytherapy


Application

  Breast cancer
  Lung cancer
  Penile cancer
  Prostate cancer
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Type Insights

The EBRT segment is estimated to witness significant growth during the forecast period.

Radiation oncology, a specialized medical field focusing on the use of radiation to treat various types of cancer, encompasses external beam radiation therapy (EBRT). EBRT utilizes high-energy beams, typically generated by a Linear Accelerator (LINAC, the most common technology), to target and destroy cancer cells. These beams can be delivered as X-rays, electrons, or other particles, such as protons. EBRT plays a crucial role in treating numerous cancer types, including breast cancer, colorectal cancer (CRC), cervical cancer, esophageal cancer, head and neck cancer, lung cancer, prostate cancer, and brain tumors. Advanced radiotherapy systems, such as CyberKnife, Gamma Knife, and TomoTherapy, are also part of the EBRT market.

Furthermore, proton therapy, which uses cyclotrons and synchrotrons, is another subset of EBRT. Among these technologies, LINAC holds the largest market share In the market. By providing precise and effective cancer treatment, these advanced technologies contribute significantly to cancer treatment centers across the US and North America, ensuring improved patient outcomes and quality of life.

Get a glance at the Radiation Oncology Industry report of share of various segments Request Free Sample

The EBRT segment was valued at USD 6.22 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

Europe is estimated to contribute 39% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and driv

BackgroundThe impact and utility of machine learning (ML)-based prediction tools for cancer outcomes including assistive diagnosis, risk stratification, and adjunctive decision-making have been largely described and realized in the high income and upper-middle-income countries. However, statistical projections have estimated higher cancer incidence and mortality risks in low and lower-middle-income countries (LLMICs). Therefore, this review aimed to evaluate the utilization, model construction methods, and degree of implementation of ML-based models for cancer outcomes in LLMICs.MethodsPubMed/Medline, Scopus, and Web of Science databases were searched and articles describing the use of ML-based models for cancer among local populations in LLMICs between 2002 and 2022 were included. A total of 140 articles from 22,516 citations that met the eligibility criteria were included in this study.ResultsML-based models from LLMICs were often based on traditional ML algorithms than deep or deep hybrid learning. We found that the construction of ML-based models was skewed to particular LLMICs such as India, Iran, Pakistan, and Egypt with a paucity of applications in sub-Saharan Africa. Moreover, models for breast, head and neck, and brain cancer outcomes were frequently explored. Many models were deemed suboptimal according to the Prediction model Risk of Bias Assessment tool (PROBAST) due to sample size constraints and technical flaws in ML modeling even though their performance accuracy ranged from 0.65 to 1.00. While the development and internal validation were described for all models included (n=137), only 4.4% (6/137) have been validated in independent cohorts and 0.7% (1/137) have been assessed for clinical impact and efficacy.ConclusionOverall, the application of ML for modeling cancer outcomes in LLMICs is increasing. However, model development is largely unsatisfactory. We recommend model retraining using larger sample sizes, intensified external validation practices, and increased impact assessment studies using randomized controlled trial designsSystematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=308345, identifier CRD42022308345.

Glioblastoma, the most aggressive form of brain cancer, remains a significant global contributor to mortality. Predictions of its increasing incidence in the coming decades underscore the need for more effective treatment strategies. Caerin 1.1 and 1.9, host defence peptides originally isolated from the skin secretions of an Australian tree frog, have exhibited tumour growth inhibition against a diverse spectrum of tumours in vitro. In this study, we reaffirm their potential by demonstrating their inhibitory impact on glioblastoma growth through CCK8 assays. Furthermore, caerin 1.1 and 1.9 effectively curtailed the migration of all tested glioblastoma cells in a cell scratch assay.Quantitative proteomic analysis was employed to investigate the molecular mechanism underlying the anti-proliferative activity.